It wouldn't be surprising to see another dip desig
Post# of 1460
Every biotech is risky, but given the gigantic unmet need for an Alzheimer's drug that works even a little bit, and the fact that AVXLD's drug is NOT going down the same old failed pathways -- and, the fact that they are uplisting AND presenting test results in the next 2 weeks -- I think that those who hang on will be rewarded.
Talking my book.